비특이성 질염에 대한 Benzydamine 국소요법의 치료효과

김승조,정재근,김수평,신종철,정난주,김종호 대한산부인과학회 1995 Obstetrics & Gynecology Science Vol.38 No.8

1992년 6월부터 1992년 9월까지 가톨릭의과대학 부속 강남성모병원 산부인과에 대하중, 소 양증, 압박감, 자연통, 성교통 및 작열감 등을 주소로 내원하여 비특이성 질염, 경질염, 및 외음부질염 등으로 진단된 28예를 대상으로 0.1% benzydamine용액을 1일 2회 5일간 질세척 한 후 다음과 같은 결과를 얻었다. 1. 대상 환자 28예중 16에는 경질염, 10예는 질염 그리고 2예는 외음부질염이었다. 2. 환자의 연령분포는 27-51세까지 였고, 평균연령은 39.6세였으며, 분만횟수는 1-2회가 20예로 가장 많았다. 3. 균배양검사 결과, E.coli 가 14례로 가장 많았으며 그 다음으로는 staphylococcus aureus 와 candida albicans 가 각각 5예씩 이었다. 4. 5일간 치료후 자각증상의 소실은 대하증이 72.4%, 소양증이 90.0% 압박감이 78.0% 자연 통이 82.8% 성교통이 81.6%, 작열감이 87.4%였다. 5. 5일간 치료후 염증성 소견의 소실은 발적이 82.8%, 부종이 80.6% 분비물 과다는 85.2% 백혈구가 66.9%였다. 6. 자각증상 및 염증성 소견 전체에 대한 치료효과도 치료 제 3일째 및 제 5일째에서 모두 유의하게 있었다. 7. 환자별 치료 효과는 현저한 효과 16예(57.1%) 중증도 효과 11예(39.3%) 및 미세 효과 1례 (3.6%) 등의 순이었다. 8. 약제의 부작용은 자각증상이나 이화학적 소견에서 발견할 수 없었다. 이상의 결과로 보아 0.1% benzydamine 용액은 안전하면서도 효과가 높은 질 세척제라고 생각된다. A clinical evaluation about therapeautic effect of 0.1% Benzydamine(Tantum Rosa) in non-specific vaginitis has been carried out in 28 patients, who visitied the Department of Obsterics and Gynecology, Catholic University Medical College from June 1st, 1992 to September 30th, 1992 . Out of 28 cases, cerico-vaginitis, vaginitis and vulvo-vaginitis were 16 cases, 10 cases and 2 cases, respectively. Ages ranged from 27 years to 51 years with a mean of 39.6 years. the most offending organism was E. coli(14 cases). After treatment , the subjective symptoms such as leukorrhea prutitus, tightness, spontaneous pain, dyspareunia nad burning were ameliorated in 72.4%, 90.0%, 78.1%,82.0%, 81.6% and 87.4% respectively, After treatment , the objective signs such as hyperemia, edema, hypersecretion and leukocytes were ameliorated in 82.8%, 80.6%,85.2% and 66.9%, respectively. Total symptomatology of the third and the fifth day after treatment were significantly lower than that of the pretreatment(p$lt;0.05, p$lt;0.001). The therapeutic effects were excellent in 16 cases(57.1%), moderate in 11 cases(39.3%) and minimal in 1 case(3.6%). There was no side effect in all patients during and after treatdment. We suggested that 0.1% benzydamine is the excellent agent in the treatment of non-specific vaginitis.

Studies on the Development of Antihyperlipidemic Drugs from Oriental Herbal Medicines(Ⅲ) -Antihyperlipidemic Effects of Herbal Prescriptions-

Jung EA,Kim YK,Kim NJ,Kim DH,Lee SI 대한약학회 2000 大韓藥學會 總會 및 學術大會 Vol.49 No.-

Effects of the Leaves of Zanthoxylum piperitum on the Formation of Lipid Peroxide In Vivo and Their Phenolic Compounds

Park JC,Hur JM,Lee JH,Sung NJ,Baek NJ,Kim MS,Park JG,Kim HJ,Choi JW 大韓藥學會 2000 大韓藥學會 總會 및 學術大會 Vol.2000 No.1

자궁경부암 항암제치료 환자에서의 Bleomycin Induced Pulmonary Toxicity 4 례

김승조,남궁성은,김세일,문봉태,홍경선,정난주,신진웅,이경숙 대한산부인과학회 1992 Obstetrics & Gynecology Science Vol.35 No.2

Bleomycin 사용으로 인한 폐 섬유화로 인하여 사망한 4례를 관찰한 결과 폐독성은 투여량에 반드시 비례하지는 않았다. Bleomycin에 의한 폐독성의 증상이 나타났을시에는 전례에서 치료에 반응하지 않고 급속히 사망하였다. 저자들은 항암효과가 탁월하고 cost effective한 항암제인 bleomycin의 사용으로 인한 폐섬유화증에 의한 사망 4례를 보고하며, 이 약제의 계속적인 사용이 필요한지 또는 부작용을 줄이며 효과면에서는 대등하다고 하는 대체 약제를 선택하여야 할 지 등에 대한 문제를 제기하는 바이다. Bleomycin has been widely used as chemotherapeutic agent for the treatment of uterine cervical cancer, Hodgkin`s disease, Malignant lymphoma and squamous cell cancer of skin, esophagus and Lung. Although Bleomycin has side effects of headache, nausea, vomiting and high fever and toxicities of skin pigmentation, hyperkeratosis and skin ulceration but most of all, interstitial pulmonary fibrosis is the most serious complication. From October, 1984 to August, 1990 in the Department of Obstetrics and Gynecology, Catholic University Medical College, we experienced 4 cases of death from Bleomycin induced pulmonary fibrosis during the courses of combination chemotherapy of VBP in patients with cervical cancer. Mean age was 51.8 and clinical stages were Ⅱ1, Ib, Ⅱa and Ⅲ (as FIGO classification). In case 1 the patient received radiation therapy concurrently with chemotherapy. In case 2 the patient received chemotherapy before and after radical hysterectomy. In case 3 the patient received chemotherapy after modified radical hysterectomy and radiation therapy. In case 4 the patient received chemotherapy after radiation therapy. Mean amount of administered Blecomycin was 343.8mg and mean duration from initial use of Bleomycin to the symptom apperance of pulmonary fibrosis was 7 and half months. Mean durations from appearance of symptom of pulmonary fibrosis to death was 3 weeks.

세균성 심내막염에 동반된 완전 방실 차단 1예

김남호,정진원,윤경호,유남진,이은미,박무림,오석규,최순호,박옥규 대한순환기학회 2003 Korean Circulation Journal Vol.33 No.6

Multiple Infarcts after Intra-arterial Carboplatin Therapy

민준홍,김주한,정용구,이남준,서중근,이훈갑 대한신경외과학회 2003 Journal of Korean neurosurgical society Vol.34 No.3

Klinefelter증후군 태아의 산전진단 1 예

송찬호,양영호,김세광,최남종 대한산부인과학회 1992 Obstetrics & Gynecology Science Vol.35 No.6

저자들은 35세의 고령 경산부에서 임신 19주에 양수천자를 시행하여 47, XXY 핵형의 Klinefelter증후군 태아를 산전 진단하였으며 유전상담후 임신종결시킨 1예를 문헌고찰과 함께 보고하는 바이다. A 35-year old woman was referred for prenatal diagnosis because of advanced maternal age. A classical 47, XXY Klinefelters syndrome was diagnosed at 19 gestational weeks in amniotic fluid cells. After counseling, the patient elected pregnancy termination. Confirmation of the prenatal cytogenetic result was obtained by analysis of blood lymphocytes after birth.

유식세포 분석기를 이용한 부인암 환자의 T세포 측정 : 초기 및 화학요법후 T세포 아형 Initial and Postchemotherapy State of T-lymphocyte Subset

이헌영,나종구,김세일,유기성,정난주,신진웅,이경숙,노정숙 대한산부인과학회 1992 Obstetrics & Gynecology Science Vol.35 No.2

부인암 환자에서 면역능 저하상태를 측정하고, 면역능 저하가 항암 화학요법의 부작용에 미치는 영향을 알아보고자 24명의 부인암 환자와 10명의 정상여성에서 유식세포 분석기를 이용하여 T세포 아형을 측정하였다. 또 항암 화학요법이 면역기능에 주는 영향과 화학요법의 부작용과의 관계를 밝히기 위해 17명의 부인암 환자에서 항암 화학요법 전과 48시간후에 T세포아형을 측정하여 다음과 같은 결과를 얻었다. 1. 임파구 수는 정상 여성에서 2422.0±236, 부인암 환자에서 1708.7±187.7로 부인암 환자에서 유의하게 감소하였다(P=0.038). 2. Th수, Ts수, Th/Ts비는 정상 여성과 부인암 환자 사이에 유의한 차이가 없었다(P$gt;0.05). 3. 항암 화학요법 전 그리고 48시간 후에 측정한 임파구 수는 화학요법 전이 1752.5±239.2, 후가 1358.1±174.7로 유의한 감소를 보였으며(P=0. 028), Ts수도 화학요법 전이 500.5±76.0, 후가 382.0±67.7로 유의한 감소를 보였다(P=0.029). 4. 항암 화학요법 전과 48시간 후에 측정한 Th수와 Th/Ts비는 유의한 차이가 없었다(P$gt;0.05). 5. 초기 Th/Ts 비가 낮은 환자는 항암 화학요법의 부작용이 심하게 나타났으며(P=0.045), 화학요법후 Th/Ts비가 낮은 환자에서도 항암 화학요법의 부작용은 심하였다(P=0.028). 6. 항암 화학요법후 Th수가 40%이상 감소한 환자(n=5)는 40%미만 감소한 환자(n=5)보다 화학요법의 부작용이 심하였다(P=0.035). 이상의 결과로 볼 때 부인암 환자에서 암 자체에 의한 면역기능의 저하가 있으며, 화학요법에 의해 면역기능은 더욱 저하되며, 면역기능 저하와 화학요법의 부작용과 유의한 연관성이 있었으며, 단일 클론 항체를 이용하여 유식세포기로 측정한 T세포 아형은 부인암 환자의 면역기능 측정 및 화학요법의 부작용 예측에 유용한 검사법임을 확인하였다. Depression of peripheral blood T-cell number and in vitro reactivity have been observed in cancer patients and cancer chemotherapeutic agents have immunosuppressive side effects. Combining the specificity of monoclonal antibody with developed technology has helped modern flow cytometry have a jajor impact in clinical evaluation of the immune status. To investigate the immune suppression of the patients with gynecologic malignancy and to predict the side effect of chemotherapy, flow cytometric analysis of T-lymphocyte subpopulations was done in 24 patients with gynecologic malignancy at initial stage and 17 patients among them at 48 hours after chemotherapy. Control group was composed of 10 healthy woman aged from 31 to 51. The results were as follows ; 1. Total lymphocytes count was 1708.7±187.7 in patients and 242.2±236 in control group, and there was significant decrease in patients compared to control group(p=0.038). 2. There was no significant difference of the number of T helper (Th) and T suppressor (Ts) and the Th/Ts ratio between patients and control group. 3. Total lymphocytes and Ts count were significantly decreased after chemotherapy (p$lt;0.03), but Th count and Th/Ts ratio were showed no significant difference. 4. The patients had low Th/Ts ratio before or after chemoterapy showed severe side effect by Zubroad performance status scale (p$lt;0.05). 5. The severe side effect was seen in the patients showed decrease of Th count over 40% than in the patients under 40% decrease after chemotherapy (p=0.035).

Identification of Unknown Bile Duct Injury in the Right Liver Graft and Adequate Anastomosis Method to Overcome Delayed Biliary Complication: A Case Report

( Taganova An ),( Lee Kw ),( Jeong Jh ),( Suh Sw ),( Yi Nj ),( Kim Hy ),( Suh Ks ) 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1

Different anatomical variations of the intrahepatic bile ducts, and in particular its right half, is one of the important risk factors for billiary complication in recipients undergoing living-donor liver transplantation (LDLT). The authors already reported high risk group of biliary injury during living donor hepatecotmy according to the anatomy of the right posterior bile duct (RPBD). We experienced a case with the bile duct injury in the graft which was unnoticed during living donor hepatectomy. 26 years old male underwent right liver hepatectomy for donation to his father 55 years old. The preoperative MRCP showed long caudal segment of RPBD, which has been reported as high risk for biliary complication in the recipient. There was no problem during donor hepatectomy and bench surgery. However, we found that RPBD was not easily identified and RPBD was partially ligated when probing was tried just before biliary anastomosis. We opened ligated RPBD. But the wall was thin. We opened damaged wall of RPBD and duct-to-duct anastomosis was done without stent. According to this case, we learned several lessons: 1) Understanding of the preoperative risk of bile duct injury during hepatectomy based on preoperative MRCP is important, 2) different bile duct division method in the high risk patient should be applied, 3) comparison of the biliary anatomy by probing the graft during bench with that of preoperative MRCP is necessary to detect unknown bile duct injury, 4) injured wall should be opened and anastomosed using healthy duct is important to reduce delayed biliary complications.